Cytomegalovirus infection
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- A herpesvirus infection caused by Cytomegalovirus. Healthy individuals generally do not produce symptoms. However, the infection may be life-threatening in affected immunocompromised patients. The virus may cause retinitis, esophagitis, gastritis, and colitis. Morphologically, it is characterized by the presence of intranuclear inclusion bodies.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Cytomegalovirus infection
- Therapeutic area
- Infectious Disease
- cytomegalovirus infection
- CMV infection
- Cytomegaloviral infection
- HCMV infection
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Severe
- MONDO ID
- MONDO:0005132
- Parent condition
- MONDO:0005794
Related records
Broader conditions (8)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Herpesviridae infectious disease
- Human disease
- Infectious disease
- Primary viral infectious disease
- Viral infectious disease
Narrower conditions (5)
- Cytomegalovirus pneumonia
- Cytomegalovirus pneumonia due to NOS2 deficiency
- Cytomegalovirus retinitis
- Fetal cytomegalovirus syndrome
- Idiopathic disseminated cytomegalovirus infection
Trials (369)
- (Val)Ganciclovir TDM in Transplant Recipients
- A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)
- A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in China
- A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection
- A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China
- A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
- A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
- A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.
- A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
- A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)
- A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
- A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir
- A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease
- A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
- A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
- A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
- A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir
- A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine
- A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy
- A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.
Approved drugs (2)
- Letermovir
- Maribavir
Drugs in development (23)
- Acyclovir Phase 3
- Acyclovir sodium Phase 3
- Adefovir dipivoxil Phase 3
- Aldesleukin Phase 1
- Artesunate Phase 3
- Brincidofovir Phase 3
- Cidofovir Phase 3
- Dextromethorphan Phase 1
- Digoxin Phase 1
- Everolimus Phase 3
- Filociclovir Phase 1
- Foscarnet Phase 3
- Ganciclovir Phase 3
- Levocarnitine Phase 3
- MCMV-3068A Phase 2
- Mycophenolic acid Phase 3
- Phenol Phase 3
- Sevirumab Phase 1
- TCN-202 Phase 1
- Temozolomide Phase 1
Other linked drugs (3)
- Adimlecleucel
- Fomivirsen sodium
- Regavirumab